Hypercholesterolemia

Metabolic·MeSH: Hypercholesterolemia

Prevalence

0.5 / 100K

31 drugs in development·18 companies·24 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
colesevelam	Impax Laboratories, LLC (IPXL)
colestipol	ANI PHARMACEUTICALS INC (ANIP)
Evkeeza	Ultragenyx Pharmaceutical Inc. (RARE)
fenofibrate	ANI PHARMACEUTICALS INC (ANIP)
pitavastatin	Mylan II B.V. (MYL)

Phase 3(10)

Drug	Company
Enlicitide Decanoate	Merck & Co., Inc. (MRK)
Evinacumab	Ultragenyx Pharmaceutical Inc. (RARE)
inclisiran	MEDICINES CO /DE (MDCO)
inclisiran sodium 300 mg in	Novartis AG (NVS)
isis 301012	TG THERAPEUTICS, INC. (TGTX)
rosuvastatin	Sanofi (SNY)
rosuvastatin active	Sanofi (SNY)
spc ezetimibe/rosuvastatin	Sanofi (SNY)
syh2053	NYMOX PHARMACEUTICAL CORP (NYMXF)
Zodasiran	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Phase 2(5)

Drug	Company
alirocumab	REGENERON PHARMACEUTICALS, INC. (REGN)
aro-ang 3	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
inclisiran	Novartis AG (NVS)
mgl-3196	MADRIGAL PHARMACEUTICALS, INC. (MDGL)
sln365	Silence Therapeutics Plc (SLN)

Phase 1(7)

Drug	Company
aem-28	Capstone Holding Corp. (CAPS)
verve-101	Verve Therapeutics, Inc. (VERV)
verve-102	Verve Therapeutics, Inc. (VERV)
VERVE-102	Travere Therapeutics, Inc. (TVTX)
verve-201	Verve Therapeutics, Inc. (VERV)
verve-301	Verve Therapeutics, Inc. (VERV)
vxx-401	Vaxxinity, Inc. (VAXX)

Preclinical(3)

Phase 4(1)

Drug	Company
Inclisiran	Novartis AG (NVS)

BioSniper tracks 31 drugs in development for Hypercholesterolemia across 18 companies.

There are 24 clinical trials targeting Hypercholesterolemia tracked by BioSniper.

The estimated prevalence of Hypercholesterolemia is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.